Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CGON CG Oncology	$26.48 0.0%	$26.13	$14.80 ▼ $40.47	$2.02B	0.87	967,256 shs	119,685 shs
DNA Ginkgo Bioworks	$12.22 -1.1%	$11.77	$5.00 ▼ $16.85	$722.65M	1.5	1.53 million shs	1.10 million shs
IBRX ImmunityBio	$2.30 -1.9%	$2.62	$1.83 ▼ $7.48	$2.17B	0.12	7.87 million shs	4.47 million shs
NMRA Neumora Therapeutics	$1.77 +0.3%	$1.43	$0.61 ▼ $17.19	$285.84M	2.91	1.99 million shs	224,804 shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CGON CG Oncology	-2.03%	+3.72%	+2.40%	+0.95%	-27.47%
DNA Ginkgo Bioworks	-2.76%	+7.25%	-10.87%	+71.73%	+64.79%
IBRX ImmunityBio	-1.68%	+3.54%	-11.70%	-10.00%	-44.15%
NMRA Neumora Therapeutics	+1.15%	+9.32%	-22.81%	+144.89%	-84.78%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CGON CG Oncology	1.2225 of 5 stars	3.5	0.0	2.2	0.8	0.0
DNA Ginkgo Bioworks	1.0202 of 5 stars	1.2	3.0	2.4	2.5	0.6
IBRX ImmunityBio	2.4003 of 5 stars	3.6	1.0	3.1	1.7	0.6
NMRA Neumora Therapeutics	2.5551 of 5 stars	3.1	3.0	2.3	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CGON CG Oncology	3.00	Buy	$54.30	105.10% Upside
DNA Ginkgo Bioworks	2.33	Hold	$9.50	-22.25% Downside
IBRX ImmunityBio	3.20	Buy	$10.75	368.41% Upside
NMRA Neumora Therapeutics	2.22	Hold	$7.14	304.69% Upside

Current Analyst Ratings Breakdown

Latest CGON, NMRA, DNA, and IBRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/26/2025	IBRX ImmunityBio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$24.00
8/25/2025	DNA Ginkgo Bioworks	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sell ➝ Sell	$6.00 ➝ $9.00
8/18/2025	CGON CG Oncology	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$55.00
8/14/2025	IBRX ImmunityBio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$24.00
8/8/2025	DNA Ginkgo Bioworks	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
8/5/2025	IBRX ImmunityBio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
7/25/2025	IBRX ImmunityBio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
7/16/2025	CGON CG Oncology	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$68.00 ➝ $53.00
7/16/2025	NMRA Neumora Therapeutics	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$4.00 ➝ $5.00
7/10/2025	CGON CG Oncology	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$40.00
7/8/2025	IBRX ImmunityBio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00

(Data available from 8/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CGON CG Oncology	$1.14M	1,770.81	N/A	N/A	$8.79 per share	3.01
DNA Ginkgo Bioworks	$227.04M	3.19	N/A	N/A	$10.35 per share	1.18
IBRX ImmunityBio	$14.74M	147.18	N/A	N/A	($0.60) per share	-3.83
NMRA Neumora Therapeutics	N/A	N/A	N/A	N/A	$1.13 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CGON CG Oncology	-$88.04M	-$1.77	N/A	N/A	N/A	-15,945.17%	-19.37%	-18.72%	11/11/2025 (Estimated)
DNA Ginkgo Bioworks	-$547.03M	-$5.86	N/A	N/A	N/A	-136.56%	-43.25%	-22.29%	11/11/2025 (Estimated)
IBRX ImmunityBio	-$413.56M	-$0.48	N/A	N/A	N/A	-648.57%	N/A	-113.86%	11/11/2025 (Estimated)
NMRA Neumora Therapeutics	-$243.79M	-$1.57	N/A	N/A	N/A	N/A	-98.95%	-87.68%	11/11/2025 (Estimated)

Latest CGON, NMRA, DNA, and IBRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/8/2025	Q2 2025	CGON CG Oncology	-$0.49	-$0.54	-$0.05	-$0.54	$0.11 million	N/A
8/7/2025	Q2 2025	DNA Ginkgo Bioworks	-$1.44	-$1.10	+$0.34	-$1.10	$41.60 million	$49.60 million
8/6/2025	Q2 2025	NMRA Neumora Therapeutics	-$0.38	-$0.33	+$0.05	-$0.33	N/A	N/A
8/5/2025	Q2 2025	IBRX ImmunityBio	-$0.10	-$0.10	N/A	-$0.10	$21.95 million	$26.43 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CGON CG Oncology	N/A	N/A	N/A	N/A	N/A
DNA Ginkgo Bioworks	N/A	N/A	N/A	N/A	N/A
IBRX ImmunityBio	N/A	N/A	N/A	N/A	N/A
NMRA Neumora Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CGON CG Oncology	N/A	22.15	22.15
DNA Ginkgo Bioworks	N/A	5.41	5.41
IBRX ImmunityBio	N/A	4.11	3.98
NMRA Neumora Therapeutics	0.11	10.54	10.54

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CGON CG Oncology	26.56%
DNA Ginkgo Bioworks	78.63%
IBRX ImmunityBio	8.58%
NMRA Neumora Therapeutics	47.65%

Insider Ownership

Company	Insider Ownership
CGON CG Oncology	7.40%
DNA Ginkgo Bioworks	9.72%
IBRX ImmunityBio	76.79%
NMRA Neumora Therapeutics	26.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CGON CG Oncology	61	76.25 million	70.61 million	Optionable
DNA Ginkgo Bioworks	640	59.20 million	53.45 million	Optionable
IBRX ImmunityBio	590	945.26 million	219.39 million	Optionable
NMRA Neumora Therapeutics	108	161.95 million	118.54 million	Optionable

CGON, NMRA, DNA, and IBRX Headlines

Recent News About These Companies

T. Rowe Price Investment Management Inc. Sells 2,899,770 Shares of Neumora Therapeutics, Inc. $NMRA

August 27 at 4:50 AM | marketbeat.com

Neumora Therapeutics Initiates Phase 1 Study for Schizophrenia Drug NMRA-861

August 20, 2025 | msn.com

Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives $7.14 Average PT from Brokerages

August 18, 2025 | americanbankingnews.com

Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Average Recommendation of "Hold" by Analysts

August 16, 2025 | marketbeat.com

Neumora Therapeutics, Inc. (NASDAQ:NMRA) Shares Bought by XTX Topco Ltd

August 14, 2025 | marketbeat.com

Federated Hermes Inc. Makes New Investment in Neumora Therapeutics, Inc. (NASDAQ:NMRA)

August 11, 2025 | marketbeat.com

Q3 EPS Estimate for Neumora Therapeutics Boosted by Analyst

August 11, 2025 | marketbeat.com

William Blair Issues Positive Outlook for NMRA Earnings

August 11, 2025 | marketbeat.com

Neumora Therapeutics, Inc.: Promising Potential in Obesity Therapeutics with NMRA-215

August 7, 2025 | tipranks.com

Neumora outlines six upcoming clinical catalysts and prioritizes obesity program with NMRA-215

August 7, 2025 | msn.com

Neumora Therapeutics, Inc. (NMRA) Q2 2025 Earnings Call Transcript

August 7, 2025 | seekingalpha.com

Neumora Therapeutics Reports Q2 2025 Financial Results

August 7, 2025 | tipranks.com

Neumora Therapeutics reports Q2 EPS (33c), consensus (37c)

August 6, 2025 | msn.com

Neumora (NMRA) Q2 Loss Improves 10%

August 6, 2025 | aol.comA

Neumora Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

August 6, 2025 | globenewswire.com

Neumora Therapeutics (NMRA) Expected to Announce Earnings on Wednesday

July 30, 2025 | marketbeat.com

Mizuho Raises Price Target for Neumora (NMRA), Keeps Outperform Rating

July 30, 2025 | msn.com

5 Alzheimer’s Readouts To Watch

July 28, 2025 | biospace.comB

Neumora Therapeutics to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025

July 23, 2025 | globenewswire.com

Mizuho Lifts PT on Neumora Therapeutics (NMRA) to $5 from $4, Keeps Outperform Rating

July 20, 2025 | finance.yahoo.com

Neumora Therapeutics, Inc.: Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-861

July 10, 2025 | finanznachrichten.de

New MarketBeat Followers Over Time

Media Sentiment Over Time

CGON, NMRA, DNA, and IBRX Company Descriptions

CG Oncology NASDAQ:CGON

$26.48 -0.01 (-0.02%)

As of 02:14 PM Eastern

CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.

Ginkgo Bioworks NYSE:DNA

$12.22 -0.13 (-1.06%)

As of 02:15 PM Eastern

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

ImmunityBio NASDAQ:IBRX

$2.30 -0.05 (-1.92%)

As of 02:14 PM Eastern

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.

Neumora Therapeutics NASDAQ:NMRA

$1.76 +0.01 (+0.28%)

As of 02:14 PM Eastern

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time